Bevacizumab biosimilar - Bio-Thera SolutionsAlternative Names: BAT-1706
Latest Information Update: 14 Feb 2017
At a glance
- Originator Bio-Thera Solutions
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 14 Jun 2016 Preclinical trials in Cancer in New Zealand (IV) before June 2016 (ACTRN12616000283471)